维普中文期刊产品整合服务
185篇 您的检索式:作者名="Deviere"
    题名 作者 年代 出处 被引量
1Evaluation of Fujinon intelligent chromo endoscopy-assisted capsule endoscopy in patients with obscure gastroenterology bleeding显示文摘AIM:To investigate the potential benef it of Fujinon in-telligent chromo endoscopy(FICE)-assisted small bowel capsule endoscopy(SBCE)for detection and character-ization of small bowel lesions in patients with obscure gastroenterology bleeding(OGIB).METHODS:The SBCE examinations(Pillcam SB2,Giv-en Imaging Ltd)were retrospectively analyzed by two GI fellows(observers)with and without FICE enhance-ment.Randomization was such that a fellow did not assess the same examination with and without FICE enhancement.The senior consultant described f indings as P0,P1 and P2 lesions(non-pathological,intermedi-ate bleed potential,high bleed potential),which were considered as reference f indings.Main outcome mea-surements:Inter-observer correlation was calculated using kappa statistics.Sensitivity and specif icity for P2 lesions was calculated for FICE and white light SBCE.RESULTS:In 60 patients,the intra-class kappa cor-relations between the observers and reference f indings were 0.88 and 0.92(P2),0.61 and 0.79(P1),for SBCE using FICE and white light,respectively.Overall 157 le-sions were diagnosed using FICE as compared to 114 with white light SBCE(P = 0.15).For P2 lesions,the sensitivity was 94% vs 97% and specif icity was 95% vs 96% for FICE and white light,respectively.Five(P2 le-sions)out of 55 arterio-venous malformations could be better characterized by FICE as compared to white light SBCE.Significantly more P0 lesions were diagnosed when FICE was used as compared to white light(39 vs 8,P < 0.001).CONCLUSION:FICE was not better than white light for diagnosing and characterizing signif icant lesions on SBCE for OGIB.FICE detected signif icantly more non-pathological lesions.Nevertheless,some vascular le-sions could be more accurately characterized with FICE as compared to white light SBCE.Tarun Gupta Mostafa Ibrahim Jacques Deviere André Van Gossum 2011World Journal of Gastroenterology2011,17,41:8
2Carbon dioxide for gut distension during digestive endoscopy:Technique and practice survey显示文摘AIM:To assess the adoption of Carbon dioxide(CO2)insufflation by endoscopists from various European countries,and its determinants.METHODS:A survey was distributed to 580 endoscopists attending a live course on digestive endoscopy.RESULTS:The response rate was 24.5%.Fewer than half the respondents(66/142,46.5%)were aware of the fact that room air can be replaced by CO2 for gut distension during endoscopy,and 4.2%of respondents were actually using CO2 as the insufflation agent.Endoscopists aware of the possibility of CO2 insufflation mentioned technical difficulties in implementing the system and the absence of significant advantages of CO2 in comparison with room air as barriers to adoption in daily practice(84%and 49%of answers,respectively;two answers were permitted for this item).CONCLUSION:Based on this survey,adoption of CO2 insufflation during endoscopy seems to remain relatively exceptional.A majority of endoscopists were not aware of this possibility,while others were not aware of recent technical developments that facilitate CO2 implementation in an endoscopy suite.Filip Janssens Jacques Deviere Pierre Eisendrath Jean-Marc Dumonceau 2009World Journal of Gastroenterology2009,15,12:6
3New challenges in perioperative management of pancreatic cancer显示文摘Pancreatic ductal adenocarcinoma(PDAC)is the fourth leading cause of cancer-related death in the industrialized world.Despite progress in the understanding of the molecular and genetic basis of this disease,the5-year survival rate has remained low and usually does not exceed 5%.Only 20%-25%of patients present with potentially resectable disease and surgery represents the only chance for a cure.After decades of gemcitabine hegemony and limited therapeutic options,more active chemotherapies are emerging in advanced PDAC,like 5-Fluorouracil,folinic acid,irinotecan and oxaliplatin and nab-paclitaxel plus gemcitabine,that have profoundly impacted therapeutic possibilities.PDAC is considered a systemic disease because of the high rate of relapse after curative surgery in patients with resectable disease at diagnosis.Neoadjuvant strategies in resectable,borderline resectable,or locally advanced pancreatic cancer may improve outcomes.Incorporation of tissue biomarker testing and imaging techniques into preoperative strategies should allow clinicians to identify patients who may ultimately achieve curative benefit from surgery.This review summarizes current knowledge of adjuvant and neoadjuvant treatment for PDAC and discusses the rationale for moving from adjuvant to preoperative and perioperative therapeutic strategies in the current era of more active chemotherapies and personalized medicine.We also discuss the integration of good specimen collection,tissue biomarkers,and imaging tools into newly designed preoperative and perioperative strategies.Francesco Puleo Raphaёl Maréchal Pieter Demetter Maria-Antonietta Bali Annabelle Calomme Jean Closset Jean-Baptiste Bachet Jacques Deviere Jean-Luc Van Laethem 2015World Journal of Gastroenterology2015,21,8:4
4European Society of Gastrointestinal Endoscopy (ESGE)Guideline: Prophylaxis of post-ERCP pancreatitis显示文摘J.-M. Dumonceau A. Andriulli J. Deviere A. Mariani J. Rigaux T. Baron P. Testoni 2010Endoscopy2010,,06:4
5SJGT14082900000151显示文摘Jean-Marc Dumonceau Angelo Andriulli B. Elmunzer Alberto Mariani Tobias Meister Jacques Deviere Tomasz Marek Todd Baron Cesare Hassan Pier Testoni Christine Kapral 2014Endoscopy2014,,:3
6Pulmonary hypertension after transjugular intrahepatic portosystemic shunt: Effects on right ventricular function显示文摘P Van der Linden O Le Moine M Ghysels M Ortinez J Deviere 1996Hepatology1996,,5:2
7Antibiotic prophy-laxis for infectious complications after therapeutic endo- scopic retrograde cholangiopancreatography: a random- ized, double-blind, placebo-controlled study显示文摘Byl B Deviere J Struelens M J 1995Clin ln- fectDis1995,20,5:1
8Endoscopic management of chronic pancreatitis 显示文摘Delhaye M Matos C Deviere J 2003Gastrointest Endose Clin N Am2003,13,4:1
9New frontiers in the pharmacological prevention of post-ERCP pancreatitis:The Cytokines JOP显示文摘Demols A Deviere J 2003J Pancreas (Online)2003,4,1:1
10Management of anticoagulants before and after endoscopy显示文摘HITFLET A DEVIERE J 2003J Gastroenterol2003,17,5:1
11New frontiers in the pharmacological prevention of post-ERCP pancreatitis:The Cytokines显示文摘Demols A Deviere J 2003JOP2003,4,1:1
12Analysis of hormonal steroids in fish plasma and bile by coupling solid-phase extraction to GC/MS 显示文摘Budzinski H Devier M H Labadie P 2006Anal Bioanal Chem2006,386,5:1
13Barrett's oesophagus:the new endoscopic modalities have a future显示文摘Deviere J 2005Gut2005,54,1:1
14Choledochal cysts:comparison of findings at MR cholangiopancreatography and endo,opic retrograde cholangiopancreatography in eight patients显示文摘Matos C Nicaise N Deviere J 1998Radiology1998,209,2:1
15Splenic Parenchymal Complication of Pancreatitis:CT Findings and Natural History显示文摘Rypens F Deviere J Zalcman M 1997J Comput Assist Tomogr1997,21,1:1
16European Society of Gastrointestinal Endoscopy (ESGE)Guideline: Prophylaxis of post-ERCP pancreatitis显示文摘J.-M. Dumonceau A. Andriulli J. Deviere A. Mariani J. Rigaux T. Baron P. Testoni 2010Endoscopy2010,,06:1
17European Society of Gastrointestinal Endoscopy (ESGE) Guideline:prophylaxis of post-ERCP pancreatitis显示文摘Dumonceau JM Andriulli A Deviere J 2010Endoscopy2010,42,:1
18Interleukin-10 reduces the incldence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography显示文摘Deviere J le-Moine O 2001Gastroenterology2001,120,2:1
19European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis显示文摘DUMONCEAU J M ANDRIULLI A DEVIERE J 2010Endoscopy2010,42,6:1
20Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography显示文摘Deviere J Moine OL Vanlacthem JL 2001Gastroenterology2001,120,:1
返回顶部 每页显示:
共10页 首页 上一页 第1页 下一页 末页 /10 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费